Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | FKBP5 | Q13451 | 1/20 | 0.35 |
| ▸ | GPR3 | P46089 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoromethanesulfonic Acid SCHEMBL64156 | 0.82 | GPR3 (0.41) | GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL11578075 | 0.79 | ALDH1A1 (0.52) | ALDH1A1FKBP5GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL11579809 | 0.79 | ALDH1A1 (0.52) | ALDH1A1FKBP5GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL997394 | 0.78 | GPR3 (0.34) | GPR3 | |
| Trifluoromethanesulfonic Acid SCHEMBL5571529 | 0.76 | GPR3 (0.32) | GPR3 | |
| Benzimidazole SCHEMBL3403941 | 0.72 | GPR3 (0.36) | ALDH1A1GPR3 | |
| SCHEMBL8715817 | 0.70 | CA2 (0.37) | ALDH1A1 | |
| Trifluoromethanesulfonic Acid SCHEMBL8717967 | 0.70 | KCNH2 (0.38) | GPR3 | |
| Imidazole SCHEMBL28944594 | 0.68 | ALDH1A1 (0.62) | ALDH1A1FKBP5 | |
| Trifluoromethanesulfonamide SCHEMBL7921865 | 0.67 | ALDH1A1 (0.54) | ALDH1A1FKBP5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1569927-B1 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-07-16 | — | — | EP | disclosed |
| US-7358268-B2 | Imidazole derivatives as factor Xa inhibitors | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-04-15 | — | — | US | disclosed |
| EP-1569927-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2005-09-07 | — | — | EP | disclosed |
| EP-1479674-A1 | Imidiazole-derivatives as factor xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-11-24 | — | — | EP | disclosed |
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-09-02 | — | — | US | disclosed |
| WO-2004050636-A2 | IMIDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | WO | disclosed |
| EP-1426364-A1 | Imidazole-derivatives as factor Xa inhibitors | Aventis Pharma Deutschland GmbH (DE) | 2004-06-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171604-A1 | Imidazole derivatives as factor Xa inhibitors | TFPI, F11, TFPI2 | ALDH1A1 1152/4885FKBP5 799/4885GPR3 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.